Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients

NCT05525650 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Mite Allergy
Rhinitis, Allergic
House Dust Mite Rhinitis

Interventions

DRUG: House Dust Mite Extract, Dermatophagoides Farinae

Sponsor

RAPHAS